XNAS · Healthcare · Health Information Services
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Altaris agreed to buy Simulations Plus, making the quarter secondary despite a solid **$0.07 EPS beat** and **$22M revenue**. In healthcare software, the key issue is takeover execution, though margins stayed ugly at **-81.7%**.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-09 | Q3 2026 | 0.23 | 0.30 | +30.43% | $21.9M | ✅ Beat | -0.65% | -0.60% | — |
| 2026-04-09 | Q2 2026 | 0.29 | 0.35 | +20.69% | $24.3M | ✅ Beat | +12.87% | +8.70% | +28.41% |
| 2026-01-08 |
| Q1 2026 |
| 0.19 |
| 0.17 |
| -10.53% |
| $18.4M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-12-01 | Q4 2025 | 0.11 | 0.10 | -9.09% | $17.5M | ❌ Miss | — | — | — |
| 2025-07-14 | Q3 2025 | 0.26 | 0.45 | +73.08% | $20.4M | ✅ Beat | -3.84% | -24.79% | -16.83% |
| 2025-04-03 | Q2 2025 | 0.26 | 0.31 | +19.23% | $22.4M | ✅ Beat | +7.83% | +8.08% | +41.13% |
| 2025-01-07 | Q1 2025 | 0.17 | 0.17 | +0.00% | $18.9M | ➖ Inline | -7.17% | -5.36% | +17.08% |
| 2024-10-23 | Q4 2024 | 0.03 | 0.06 | +100.00% | $18.7M | ✅ Beat | -8.89% | -15.60% | -7.83% |
Showing last 8 quarters.